Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:ECIANASDAQ:IRIXNASDAQ:NRXSNASDAQ:NXL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeECIAEncision$0.35$0.43$0.12▼$0.57$4.16M0.695,097 shs500 shsIRIXIRIDEX$0.98-1.0%$1.03$0.78▼$2.58$16.45M0.6947,342 shs134,601 shsNRXSNeurAxis$3.03$2.17$1.33▼$6.20$21.86M3.34403,171 shs434,169 shsNXLNexalin Technology$1.23+1.7%$1.69$0.53▼$4.49$21.13M4.671.24 million shs30,782 shsA Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceECIAEncision0.00%-2.78%-16.67%-26.64%-30.00%IRIXIRIDEX-1.03%-2.97%-19.67%-34.88%-62.16%NRXSNeurAxis0.00%+34.67%+24.54%+31.17%+4.12%NXLNexalin Technology+1.65%-3.15%-29.71%-57.14%+6.96%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationECIAEncisionN/AN/AN/AN/AN/AN/AN/AN/AIRIXIRIDEX0.7927 of 5 stars0.04.00.00.02.41.70.0NRXSNeurAxisN/AN/AN/AN/AN/AN/AN/AN/ANXLNexalin Technology2.7812 of 5 stars3.55.00.00.01.13.30.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceECIAEncision 0.00N/AN/AN/AIRIXIRIDEX 0.00N/AN/AN/ANRXSNeurAxis 0.00N/AN/AN/ANXLNexalin Technology 3.00Buy$5.00306.50% UpsideCurrent Analyst Ratings BreakdownLatest ECIA, NXL, IRIX, and NRXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/24/2025NXLNexalin TechnologyMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold ➝ Buy$5.00(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookECIAEncision$6.59M0.63N/AN/A$0.14 per share2.50IRIXIRIDEX$48.80M0.34N/AN/A$0.59 per share1.66NRXSNeurAxis$2.69M8.14N/AN/A($0.27) per share-11.22NXLNexalin Technology$131.07K161.21N/AN/A$0.43 per share2.86Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateECIAEncision-$690K-$0.04N/A∞N/A-8.96%-32.90%-15.51%7/14/2025 (Estimated)IRIXIRIDEX-$9.57M-$0.43N/A∞N/A-22.79%-192.95%-33.97%8/6/2025 (Estimated)NRXSNeurAxis-$14.63M-$1.19N/A∞N/A-492.76%N/A-641.25%N/ANXLNexalin Technology-$4.65M-$0.83N/A∞N/A-3,407.98%-187.59%-167.21%N/ALatest ECIA, NXL, IRIX, and NRXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025IRIXIRIDEX-$0.10-$0.10N/A-$0.10$12.10 million$11.90 million5/13/2025Q1 2025NXLNexalin Technology-$0.10-$0.15-$0.05-$0.15$0.04 million$0.04 million3/27/2025Q4 2024IRIXIRIDEX-$0.05-$0.05N/A-$0.05$12.80 million$12.70 million3/14/2025Q4 2024NXLNexalin TechnologyN/A-$0.28N/A-$0.28N/A$0.03 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthECIAEncisionN/AN/AN/AN/AN/AIRIXIRIDEXN/AN/AN/AN/AN/ANRXSNeurAxisN/AN/AN/AN/AN/ANXLNexalin TechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioECIAEncision0.111.670.98IRIXIRIDEX0.551.540.85NRXSNeurAxisN/A0.240.23NXLNexalin TechnologyN/A16.4215.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipECIAEncision8.20%IRIXIRIDEX20.10%NRXSNeurAxis11.77%NXLNexalin Technology0.65%Insider OwnershipCompanyInsider OwnershipECIAEncision36.75%IRIXIRIDEX7.30%NRXSNeurAxis26.40%NXLNexalin Technology24.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableECIAEncision3011.88 million7.51 millionNot OptionableIRIXIRIDEX12016.79 million15.42 millionOptionableNRXSNeurAxis197.22 million6.09 millionNot OptionableNXLNexalin Technology317.18 million10.11 millionNot OptionableECIA, NXL, IRIX, and NRXS HeadlinesRecent News About These CompaniesReviewing Nexalin Technology (NASDAQ:NXL) and Gadsden Properties (OTCMKTS:GADS)May 16, 2025 | americanbankingnews.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer’s Program Amid Encouraging DataMay 13, 2025 | finance.yahoo.comNexalin Technology Reconstitutes Scientific Advisory Board with Leading Experts to Advance Alzheimer's Program Amid Encouraging DataMay 13, 2025 | globenewswire.comNexalin Technology, Inc. Closes Public Offering of 3,850,000 Shares at $1.30 Per Share, Raising $5.0 MillionMay 6, 2025 | quiverquant.comNexalin Technology Announces Closing of Previously Announced $5.0 Million Underwritten Public OfferingMay 6, 2025 | globenewswire.comNexalin Technology Announces Pricing of $5.0 Million Public Offering of Common StockMay 5, 2025 | globenewswire.comNexalin Technology, Inc. Plans Q-Submission to FDA for Gen-2 SYNC System Targeting Cognitive DisordersMay 1, 2025 | quiverquant.comNexalin Technology Initiates FDA Q-Submission Process for Gen-2 SYNC Following Encouraging Data and Preliminary FDA FeedbackMay 1, 2025 | globenewswire.comNexalin Technology receives IRB approval in Brazil, begins trialApril 24, 2025 | markets.businessinsider.comNexalin Technology Receives IRB Approval in Brazil and Begins Clinical Trial for Anxiety and InsomniaApril 24, 2025 | globenewswire.comNexalin completes five phases of virtual clinic, digital research systemApril 24, 2025 | markets.businessinsider.comNexalin Technology files $50M common stock offeringApril 23, 2025 | msn.comNexalin Technology Announces Completion of Phases One Through Five of its Virtual Clinic and Digital Ecosystem for HALO™ Clinical Research and Patient ManagementApril 23, 2025 | globenewswire.comNexalin Technology expresses ‘strong support’ for Health Tech Investment ActApril 22, 2025 | markets.businessinsider.comNexalin Technology, Inc. Supports Health Tech Investment Act to Enhance Medicare Reimbursement for AI-Enabled Medical DevicesApril 21, 2025 | quiverquant.comNexalin Technology Expresses Strong Support for Health Tech Investment Act to Advance Medicare Reimbursement for AI-Enabled DevicesApril 21, 2025 | globenewswire.comNexalin Technology Secures USPTO Patent for Deep Intracranial Frequency Stimulation (DIFS™) Technology in Treating Substance Use DisordersApril 14, 2025 | globenewswire.comNexalin enrolls first patients, advances toward treatment in UCSD trialApril 4, 2025 | markets.businessinsider.comNexalin Technology Enrolls First Patients and Advances Toward Treatment in UCSD Clinical TrialApril 2, 2025 | globenewswire.comJoin Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on April 3March 26, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumNVIDIA Stock Surges on Bullish News: How High Could It Climb?By Thomas Hughes | May 13, 2025View NVIDIA Stock Surges on Bullish News: How High Could It Climb?Canada Goose Soars 30%—Is This Rally Built to Last?By Thomas Hughes | May 21, 2025View Canada Goose Soars 30%—Is This Rally Built to Last?ECIA, NXL, IRIX, and NRXS Company DescriptionsEncision OTCMKTS:ECIA$0.35 0.00 (0.00%) As of 05/23/2025 03:31 PM EasternEncision Inc., a medical device company, designs, develops, manufactures, and markets patented surgical instruments in the United States. The company provides active electrode monitoring (AEM) surgical instruments and monitors that enhance patient safety and patient outcomes in laparoscopic surgical procedures. Its AEM instruments product line comprises a range of endo-mechanical instruments, including scissors, graspers, and dissectors, as well as fixed-tip electrodes and suction-irrigation electrodes. The company also offers various handles, which are used for advanced laparoscopic procedures that incorporate stiffer shafts and ergonomic features; and AEM EndoShield 2 burn protection systems, as well as markets AEM monitor product line that is used in conjunction with AEM instruments. The company sells its products through a network of direct and independent sales representatives. Encision Inc. was incorporated in 1991 and is based in Boulder, Colorado.IRIDEX NASDAQ:IRIX$0.98 -0.02 (-1.54%) As of 05/23/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.NeurAxis NASDAQ:NRXS$3.03 0.00 (0.00%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.97 -0.06 (-2.11%) As of 05/23/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome. The company sells its products to healthcare companies, including hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.Nexalin Technology NASDAQ:NXL$1.23 +0.02 (+1.65%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$1.24 +0.01 (+0.81%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
